6690 related articles for article (PubMed ID: 17720652)
41. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
42. Positron emission tomography in the evaluation of stage III and IV head and neck cancer.
Teknos TN; Rosenthal EL; Lee D; Taylor R; Marn CS
Head Neck; 2001 Dec; 23(12):1056-60. PubMed ID: 11774391
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG PET/CT imaging in oncology.
Almuhaideb A; Papathanasiou N; Bomanji J
Ann Saudi Med; 2011; 31(1):3-13. PubMed ID: 21245592
[TBL] [Abstract][Full Text] [Related]
44. [The value of PET-CT imaging in malignant tumours of the head and neck].
Balink H; Krabbe CA; de Visscher JG
Ned Tijdschr Geneeskd; 2007 May; 151(21):1167-72. PubMed ID: 17557755
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
[TBL] [Abstract][Full Text] [Related]
46. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
47. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
48. The role of the breast radiologist in evaluation of breast incidentalomas detected on 18-fludeoxyglucose positron emission tomography/CT.
Dunne RM; O'Mahony D; Wilson G; McDermott R; O'Keeffe SA
Br J Radiol; 2013 Jun; 86(1026):20130034. PubMed ID: 23568361
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
50. A preliminary report on the impact of ¹⁸F-FDG PET/CT in the management of paediatric head and neck cancer.
Boktor RR; Omar WS; Mousa E; Attia I; Refaat A; Eltawdy MH; Pitman AG; Abdel-Dayem HM
Nucl Med Commun; 2012 Jan; 33(1):21-8. PubMed ID: 21968431
[TBL] [Abstract][Full Text] [Related]
51. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
52. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT.
Strobel K; Haerle SK; Stoeckli SJ; Schrank M; Soyka JD; Veit-Haibach P; Hany TF
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):919-27. PubMed ID: 19205699
[TBL] [Abstract][Full Text] [Related]
53. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
54. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).
Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH
Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography for benign and malignant disease.
Visioni A; Kim J
Surg Clin North Am; 2011 Feb; 91(1):249-66. PubMed ID: 21184913
[TBL] [Abstract][Full Text] [Related]
56. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
57. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
58. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
59. Performance of FDG PET/CT in the clinical management of breast cancer.
Groheux D; Espié M; Giacchetti S; Hindié E
Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
[TBL] [Abstract][Full Text] [Related]
60. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
